Journal of Oncology / 2019 / Article / Tab 3

Research Article

Immunomodulatory Effect after Irreversible Electroporation in Patients with Locally Advanced Pancreatic Cancer

Table 3

Univariate and multivariate analyses of OS and PFS in patients.

CharacteristicOSPFS
Univariate analysisMultivariate analysisUnivariate analysisMultivariate analysis
HR95%CIPHR95%CIPHR95%CIPHR95% CIP

Age (years)≤ 60 / > 600.7530.163-3.3770.711NI0.9880.379-2.5770.981NI
GenderFemale / Male8.5350.994-72.5630.055NI1.5350.577-4.0840.391NI
Tumor size (cm)>4 / 2~4 / ≤ 21.4050.405-4.8760.592NI1.0190.412-2.5220.967NI
Tumor gradePoor / Moderate / Well2.7540.668-11.3540.161NI0.9100.391-2.1170.827NI
Tumor siteHead / Body / Tail3.7780.743-19.2040.109NI0.8480.393-1.8300.674NI
WBC (109)≤ 10 / > 100.7330.087-6.1640.775NI1.0190.412-2.5220.967NI
HGB (g/L)≤ 120 / > 1200.5440.121-2.4450.427NI1.2020.377-4.2800.777NI
PLT (109)≤ 300 / > 3001.5880.289-8.7210.595NI0.4770.107-2.1160.330NI
ALT (U/L)≤ 40 / > 400.9950.191-5.1810.995NI0.4090.117-1.4310.162NI
AST (U/L)≤ 40 / > 400.0330.000-67.6620.382NI0.5960.168-2.1120.423NI
ALP (U/L)≤ 100 / > 1000.8320.185-3.7420.811NI0.5220.193-1.4170.202NI
GGT (U/L)≤ 45 / > 451.4040.310-6.3650.660NI0.4180.136-1.2890.129NI
ALB (g/L)≤ 40 / > 400.5720.066-4.9390.611NI0.9240.206-4.1490.918NI
TBIL (umol/L)≤ 20.5 / > 20.50.0330.000-67.6620.382NI0.5960.168-2.1120.423NI
IBIL (umol/L)≤ 15 / > 150.0400.000-95.7740.530NI1.1480.328-4.0220.829NI
CRP (ng/L)> 3 / ≤ 38.3281.443-48.0630.0182.4580.048-125.030.6541.0240.275-3.8170.972NI
CEA (ng/mL)≤ 5 / > 50.9990.193-5.1610.999NI2.1060.805-5.5120.129NI
CA19-9 (U/ml)≤ 35 / > 350.8650.165-4.5540.868NI2.6350.573-11.5230.178NI
CD4+ T cell variationElevated/Non-elevated0.2140.041-1.1270.069NI0.9200.343-2.4700.869NI
CD8+ T cell variationElevated/Non-elevated0.0560.006-0.4900.0090.0390.002-0.7800.0340.3540.122-1.0260.0460.4180.138-0.9540.049
NK cell variationElevated/Non-elevated0.1440.025-0.8160.0290.1840.005-6.7450.3570.8170.293-2.2770.700NI
Treg cell variationDecreased/Non-decreased0.1650.033-0.8200.0281.0560.026-43.3650.9770.4520.166-1.2280.119NI
IL-2 variationElevated/Non-elevated0.3930.075-2.0670.270NI0.4080.116-1.4380.163NI
IL-6 variationDecreased/Non-decreased0.8510.188-3.8410.834NI0.6450.190-2.1870.482NI
IL-10 variationDecreased/Non-decreased1.2710.281-5.7570.756NI1.2620.396-4.0200.694NI
C3 variationElevated/Non-elevated1.1720.260-5.2920.837NI1.3860.419-4.5840.592NI
C4 variationElevated/Non-elevated1.2010.241-5.9740.823NI1.4580.434-4.8930.542NI
IgG variationElevated/Non-elevated4.0120.411-39.1560.232NI1.4590.237-8.9850.684NI
NLR> 1.47 / ≤ 1.475.9670.680-52.4000.107NI3.1851.068-13.6210.0393.4251.002 - 12.6160.046
PLR> 165.29 / ≤ 165.293.7520.738-19.0730.111NI1.5170.552-4.1710.419NI
PI2 / 1 / 03.8640.861-17.3330.078NI1.2920.439-3.8040.642NI
mGPS2 / 1 / 03.2641.266-8.4130.0144.2850.355-51.6730.2520.9210.284-2.9870.891NI

OS, overall survival; PFS, progression-free survival; NI, not included; Other abbreviations as in Table 1

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.